
OptiNose OPTN
Quartalsbericht 2025-Q1
hinzugefügt 14.05.2025
OptiNose EV 2011-2026 | OPTN
EV Jährlich OptiNose
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 312 M | 264 M | 169 M | 230 M | 309 M | 140 M | 68.6 M | 8.59 M | 43.2 M | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 312 M | 8.59 M | 172 M |
EV anderer Aktien in der Arzneimittelhersteller
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
6.79 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
25.3 M | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
28.5 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
737 M | - | - | $ 754 M | ||
|
Catalent
CTLT
|
16.7 B | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
3.37 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
457 M | - | -39.89 % | $ 27.7 M | ||
|
Alimera Sciences
ALIM
|
197 M | - | - | $ 142 M | ||
|
Athenex
ATNX
|
209 M | - | -23.39 % | $ 1.76 M | ||
|
Endo International plc
ENDP
|
-710 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
7.15 M | - | - | $ 36.6 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
756 M | - | - | $ 2.06 B | ||
|
Cumberland Pharmaceuticals
CPIX
|
124 M | $ 3.21 | 0.94 % | $ 45.1 M | ||
|
Cronos Group
CRON
|
3.84 B | $ 2.73 | 6.03 % | $ 1.39 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
10.2 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
284 M | - | 2.45 % | $ 38.1 M | ||
|
Jupiter Wellness
JUPW
|
3.7 M | - | - | $ 33.6 M | ||
|
Bausch Health Companies
BHC
|
29.9 B | $ 5.75 | 1.14 % | $ 2.1 B | ||
|
Harrow Health
HROW
|
2.21 B | $ 38.6 | 1.85 % | $ 1.42 B | ||
|
Aurora Cannabis
ACB
|
106 M | $ 3.71 | 5.1 % | $ 86.3 M | ||
|
Canopy Growth Corporation
CGC
|
459 M | $ 1.17 | 7.34 % | $ 126 M | ||
|
OrganiGram Holdings
OGI
|
456 M | $ 1.53 | 6.8 % | $ 402 M | ||
|
Lannett Company
LCI
|
648 M | - | 1.15 % | $ 7.11 M | ||
|
Sundial Growers
SNDL
|
-17.5 M | $ 1.53 | 6.25 % | $ 3.37 M | ||
|
Neoleukin Therapeutics
NLTX
|
-80.1 M | - | - | $ 193 M | ||
|
Evolus
EOLS
|
467 M | $ 4.63 | 4.28 % | $ 298 M | ||
|
Emergent BioSolutions
EBS
|
1.2 B | $ 8.64 | -0.29 % | $ 442 M | ||
|
Tilray
TLRY
|
1.96 B | $ 6.94 | 0.36 % | $ 4.29 B | ||
|
Organogenesis Holdings
ORGO
|
392 M | $ 2.61 | 3.78 % | $ 344 M | ||
|
Veru
VERU
|
111 M | $ 2.48 | 3.14 % | $ 334 M | ||
|
Pacira BioSciences
PCRX
|
1.68 B | $ 23.52 | -0.97 % | $ 1.09 B | ||
|
Viatris
VTRS
|
41.3 B | $ 13.97 | 0.4 % | $ 16.8 B | ||
|
PetIQ
PETQ
|
280 M | - | 1.64 % | $ 400 M | ||
|
ProPhase Labs
PRPH
|
145 M | - | - | $ 5.07 M | ||
|
cbdMD
YCBD
|
7.85 M | $ 0.76 | 5.56 % | $ 3.28 M | ||
|
Relmada Therapeutics
RLMD
|
251 M | $ 7.15 | -0.56 % | $ 282 M | ||
|
Assertio Holdings
ASRT
|
238 M | $ 18.02 | - | $ 115 M | ||
|
Radius Health
RDUS
|
700 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
220 M | - | -4.76 % | $ 65.3 M | ||
|
SCYNEXIS
SCYX
|
26.3 M | $ 1.12 | 9.8 % | $ 55.9 M | ||
|
PLx Pharma
PLXP
|
73.8 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
616 M | $ 8.2 | -0.43 % | $ 718 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
7.57 M | $ 2.29 | 5.05 % | $ 2.84 M | ||
|
Zomedica Corp.
ZOM
|
2.62 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-22.6 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
43.3 M | $ 0.88 | -4.74 % | $ 31.7 M | ||
|
Tricida
TCDA
|
506 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
10.7 M | $ 0.62 | -1.62 % | $ 2.66 M | ||
|
TherapeuticsMD
TXMD
|
26.3 M | $ 2.17 | 2.84 % | $ 25.1 M |